Stephen D. Collins

Stephen D.
Collins is Executive Chairman & President at Vetana Animal Health, Inc. since 2020.
Holds director positions at Xalud Therapeutics, Inc., Engage Therapeutics, Inc., and Cerebral Therapeutics, Inc. since 2020.
Serves as Chief Medical Officer at Bright Minds Biosciences, Inc. starting 2025.
Former roles include President, Chief Executive Officer & Director at Biscayne Pharmaceuticals, Inc., NeuroTherapeutics Pharma, Inc., and Biscayne Neurotherapeutics, Inc. Served as Chairman at Terpenoid Therapeutics, Inc. Held the position of Senior Director-Global Central Nervous System at Johnson & Johnson.
Was Director at Spinifex Pharmaceuticals Pty Ltd. Independent Director at Big Cypress Acquisition Corp.
from 2020 to 2021.
Principal roles at Abbott Laboratories, Case Western Reserve University, and The University of California, San Francisco.
Chief Scientific Officer & VP-Clinical Affairs at OVATION Pharmaceuticals, Inc. Education includes a doctorate from Case Western Reserve University and an undergraduate degree from the University of California, Berkeley.